Author

admin

Browsing

A Florida Republican is arguing that Democrats’ largely negative response to the U.S. government’s operation in Venezuela is the ‘definition of Trump Derangement Syndrome.’

Rep. Mike Haridopolos, R-Fla., represents a part of Florida that includes a significant chunk of the state’s central coastline.

‘It doesn’t take much research to find speech after speech of Democrat House members and Senate members who said that this guy is a bad guy, he should be taken out of power,’ Haridopolos told Fox News Digital.

‘Sometimes in politics, you’ve just got to say to the other side, politically, ‘Hey, we’re all Americans. This is in the best interest, clearly, of the United States.’ But they’re in a position where they’re so afraid of a Democrat primary that they will say anything to avoid having the extreme left attack them.’

He pointed out that it was the previous Democratic commander-in-chief, President Joe Biden, who raised the federal government’s bounty for Maduro’s capture to $25 million.

‘What did they expect was then going to happen? You think this guy was just going to voluntarily give up? He clearly was not. He was getting into bed with the Cubans, the Russians, the Chinese, the Iranians, even Hezbollah, as I understand. I mean, this guy was trying to create a group of enemies in an oil-rich state at our footstep,’ Haridopolos said.

Democrats and Republicans have been largely divided in their responses to the strikes in Venezuela.

Lawmakers on the left have mostly criticized the president and his officials, accusing them of illegal actions that ran afoul of the U.S. Constitution. Some progressives have even said Trump could be guilty of impeachable offenses.

The majority of GOP lawmakers praised Trump’s move as a necessary law enforcement action to get rid of a hostile actor threatening both the U.S. and the region writ large.

Haridopolos is no different, pointing out that the operation was carried out with no U.S. fatalities and relatively few among Maduro supporters in Venezuela.

He said his district is home to a number of Venezuelan refugees who were elated by President Donald Trump’s decision to strike Caracas and capture Venezuelan President Nicolás Maduro.

‘I have a large population of Venezuelans within my community, and they are absolutely overjoyed,’ the congressman said. ‘They were in essence kicked out of their own country or fled through fear … because they lost their ability to make a living, or they were being terrorized by the government because they were anti-Maduro.’

Following the U.S. strikes, Maduro and his wife were both taken to New York City, where they will be prosecuted by the U.S. Attorney’s Office in the Southern District of New York.

Maduro pleaded not guilty during his first court appearance on Monday.

This post appeared first on FOX NEWS

House Freedom Caucus leaders are drawing battle lines as lawmakers return to Capitol Hill for the second half of the 119th Congress.

The conservative group’s board of directors is sending a seven-page letter to Speaker Mike Johnson, R-La., outlining proposed policy goals on a vast array of topics from American elections, to immigration, to federal spending, taking on ‘rogue’ judges, and housing affordability.

It comes ahead of a policy forum that Johnson is hosting on Tuesday to lay out the House GOP’s agenda for 2026. Republicans are expected to huddle from 9:30 am to 6 pm at the Trump Kennedy Center, where they’ll hear from committee leaders and President Donald Trump.

Trump’s remarks are expected to rally Republicans around passing their legislative goals for the year, but several people told Fox News Digital they also anticipate him focusing heavily on the U.S. government’s recent operation in Venezuela.

The first policy goal listed by the Freedom Caucus is forcing the Senate to take up the Safeguard American Voter Eligibility (SAVE) Act, which passed the House early last year.

They’re also calling on Congress to pass legislation limiting early voting and reforming the census to only count American citizens.

On fiscal year (FY) 2026 appropriations, conservatives are calling on the House to ‘reduce or — at bare minimum keep flat total federal discretionary spending levels’ according to the document first obtained by Fox News Digital.

The recently released $174 billion spending bill that the House is expected to vote on this week would reduce current funding levels for the agencies it covers if were to pass.

Congress has yet to release information on six of its 12 remaining spending bills, however, while lawmakers face a Jan. 30 deadline to avert a government shutdown.

The Freedom Caucus is also urging Congress to crack down on the recent fraud scandal taking over Minnesota’s social programs by eliminating ‘all programs exposed as rampant with fraud and place punitive measures on states such as Minnesota that have allowed rampant fraud.’

‘Federal prosecutors have estimated that widespread fraud in Minnesota tied to Somali day care centers, COVID-era meal programs, housing, and special needs assistance programs alone could exceed $9 billion,’ the document said. ‘These revelations are startling, but just a drop in the bucket for a federal government that’s estimated to lose between $233 and $521 billion annually to fraud, according to government watchdog agencies.’

The document called for the denaturalization and deportation of ‘anyone who has committed fraud against the American taxpayer,’ specifically naming Minnesota’s Somali community, though doing so would likely require court intervention.

Conservatives’ policy roadmap also called on Congress to ‘freeze all immigration to the U.S., except for (very) temporary tourist visas’ for a temporary amount of time in order to revamp the U.S. immigration system as a whole.

In a section called ‘Stop Rogue, Activist Judges,’ the House Freedom Caucus urged the House to move forward on impeaching U.S. federal Judge James Boasberg ‘such as Judge Deborah Boardman, for reducing the sentence of a man who plotted and took steps to kill a Supreme Court Justice due to her indefensible views about transgenderism.’

An earlier push by conservatives to impeach Boasberg failed to gain traction among the wider House GOP conference, though the chamber passed ‘The No Rogue Rulings Act’ to limit the ability of district judges like Boasberg to issue nationwide injunctions.

The policy roadmap also called to radically shift America’s global priorities by completely removing the U.S. from the United Nations and halting all funding to the international body.

‘The UN is openly hostile to the United States, yet we remain its biggest source of funding. President Trump has significantly reduced wasteful spending on dangerous UN entities like UNRWA, and now Congress should go even further by enacting legislation such as H.R. 1498, the DEFUND Act, to completely withdraw the United States from the United Nations (UN) and end all funding and participation,’ the passage read.

Another section calls for banning stock trading for members of Congress, which Johnson said he would be in favor of last year.

The push to ban stock trading has gained rare bipartisan support among both Republicans and Democrats, but no such bill has yet seen a House floor vote.

Banning Sharia Law in the U.S. is also listed as one of the group’s policy goals, an effort that’s been led by Texas-based Freedom Caucus members like Reps. Chip Roy, R-Texas, and Keith Self, R-Texas, so far this Congress.

While it was founded as a group that was frequently adversarial to Republican leaders for not being conservative enough, the House Freedom Caucus has gradually gained influence within the House GOP during the 119th Congress.

Its chairman, Rep. Andy Harris, R-Md., has frequently stood alongside Johnson in his push for conservative legislative goals.

Johnson notably spoke at the group’s 10th anniversary celebration late last year. Harris and Roy also made a public show of unity alongside House GOP leaders during the recent government shutdown.

Republicans are going into this year, however, grappling with a razor-thin House majority and what’s expected to be a tough November election cycle.

This post appeared first on FOX NEWS

Switzerland announced Monday that it has frozen assets held in the country tied to Venezuelan President Nicolás Maduro and his associates following the U.S. capture of the leader in Caracas. 

‘On 5 January 2026, the Federal Council decided to freeze any assets held in Switzerland by Nicolás Maduro and other persons associated with him with immediate effect,’ the Swiss Federal Department of Foreign Affairs (FDFA) said. 

The decision, which will remain in effect for four years, aims to prevent the transfer of assets amid concerns that the funds were acquired illegally through a regime long accused of widespread corruption, according to the agency. The freeze does not apply to members of the current government, and Reuters reported that the order will affect 37 people. 

Should future legal proceedings ‘reveal that the funds were illicitly acquired, Switzerland will endeavour to use them for the benefit of the Venezuelan people,’ the FDFA said.

The council added that the asset freeze builds on existing sanctions against Venezuela, first imposed in 2018 under the Embargo Act, which includes restrictions on economic resources, travel, and specific goods. 

The new measure, enacted under the Foreign Illicit Assets Act (FIAA), now targets prominent individuals who were not covered in previous Swiss sanctions and are perceived as supporting the Venezuelan regime.

According to the FDFA, the decision was not made based on Maduro’s capture nor the legitimacy of his removal but amid concerns that his home country or others could launch legal action later to recover the potentially illegally acquired assets. 

Freezing the assets now acts as a ‘precautionary measure’ meant to preserve them for potential future proceedings, according to the Swiss authorities. 

‘The reasons behind Mr Maduro’s fall from power do not play a decisive role in asset freezes under the FIAA,’ the Federal Council said in a statement. 

‘Nor does the question of whether the fall from power occurred lawfully or in violation of international law. The decisive factor is that a fall from power has occurred and that it is now possible that the country of origin will initiate legal proceedings in the future with regard to illicitly acquired assets.’

Authorities added that the government is monitoring the situation closely and is calling for the peaceful de-escalation of the ‘volatile’ situation.

‘The situation is volatile, and several scenarios are possible in the coming days and weeks,’ the FDFA said. ‘Switzerland is closely monitoring the situation in Venezuela. It has called for de-escalation, restraint and compliance with international law, including the prohibition of the use of force and the principle of respect for territorial integrity. Switzerland has also repeatedly offered its good offices to all sides in order to find a peaceful solution to the situation.’

This post appeared first on FOX NEWS

A select group of lawmakers received their first closed-door briefing on Capitol Hill on Monday following the Trump administration’s weekend military strikes in Venezuela and the capture of President Nicolás Maduro — a meeting that quickly divided along political lines.

The roughly two-hour meeting deep in the bowels of Congress featured top administration officials providing a classified briefing to congressional leaders and the chairs and ranking members of the armed services, intelligence and foreign relations committees. 

None of the Trump officials, who included Secretary of State Marco Rubio, Attorney General Pam Bondi, CIA Director John Ratcliffe, Joint Chiefs of Staff Chair Gen. Dan ‘Raizin’ Caine and Secretary of War Pete Hegseth, spoke after the meeting. 

But a handful of lawmakers did, and questions still lingered about what exactly would come next for U.S. involvement in the country, if other similar operations would be carried out across the globe, and who exactly was running Venezuela.

House Speaker Mike Johnson, R-La., said that there was no expectation that the U.S. would be on the ground, nor would there be any ‘direct involvement in any other way beyond just coercing the interim government to to get that going.’

‘We are not at war,’ Johnson said. ‘We do not have U.S. armed forces in Venezuela, and we are not occupying that country.’

‘This is not a regime change,’ he continued. ‘This is a demand for change of behavior by a regime. The interim government is stood up now, and we are hopeful that they will be able to correct their action.’

House Foreign Affairs Committee Chair Brian Mast, R-Fl., echoed Johnson, and reiterated that the operation was a ‘specific law enforcement function that took place that took a significant obstacle out of the way for the Venezuelan people to go chart a new future.’ 

He didn’t expect further military action from the Trump administration in the country, either. 

‘These things are done before breakfast,’ Mast said. ‘They don’t do protracted war operations.’

However, Senate Minority Leader Chuck Schumer, D-N.Y., countered that the lengthy meeting ‘posed far more questions than it ever answered.’ 

One growing point of contention among lawmakers is just how directly involved the U.S. will be, given that Trump said that the U.S. would govern the country until a proper transition of power happened. 

Schumer said that the plan presented behind closed doors or the U.S. running Venezuela ‘is vague, based on wishful thinking and unsatisfying.’

‘I did not receive any assurances that we would not try to do the same thing in other countries,’ he said. ‘And in conclusion, when the United States engages in this kind of regime change and so called nation building, it always ends up hurting the United States. I left the briefing feeling that it would again.’

Schumer, along with Sens. Tim Kaine, D-Va., Adam Schiff, D-Calif., and Rand Paul, R-Ky., plan to force a vote later in the week on a war powers resolution that, if passed, would require the administration to get congressional approval before taking further military action in Venezuela. 

Senate Majority Leader John Thune, R-S.D., said that he was satisfied with the briefing and that ‘it was a very comprehensive discussion.’

Lawmakers will get another bite at the apple later in the week when Trump officials again return to Congress to provide a full briefing to lawmakers on Operation Absolute Resolve. 

Sen. Mark Warner, D-Va., and the top-ranking Democrat on the Senate Select Committee on Intelligence, lauded the military for a ‘brilliant execution’ of the mission, and noted that the region was better off without Maduro.

But, like Schumer, he was still searching for the next step. 

‘The question becomes, as policymakers, what happens the day after,’ Warner said. 

This post appeared first on FOX NEWS

Today’s pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry’s major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2025, 46 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 50 such approvals in 2024.

Big pharma largely steals the show when people discuss pharmaceutical companies, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Read on to learn more about their activities this year.

1. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 211.45 percent
Market cap: US$263.08 million
Share price: US$4.08

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein. Belapectin has been granted fast-track designation by the FDA.

In 2025, Galectin Therapeutics reported positive topline data from its Phase 2b/3 trial evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension. The results demonstrated that belapectin significantly reduced the development of new esophageal varices and stabilized liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

Galectin is currently designing its pivotal Phase 3 study intended to support a formal new drug application. Based on a December 2025 response from the FDA, the company said it believes it has achieved alignment with the agency on the patient population for its upcoming registration-level trials.

2. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

In mid-May 2025, CytomX’s share price shot up significantly after the company provided its Q1 business update and closed on a US$100 million underwritten offering of common stock.

In the update, CytomX included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer. The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. In its Q3 update, CytomX reported it plans to initiate a Phase 1b study of CX-2051 in combination with bevacizumab to treat colorectal cancer, also expected in the first quarter of the new year.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) Keytruda in patients with metastatic melanoma. The company released initial translational data in November.

3. Eton Pharmaceuticals (NASDAQ:ETON)

Year-to-date gain: 25.37 percent
Market cap: US$450.53 million
Share price: US$16.80

Eton Pharmaceuticals is a high-growth pharmaceutical company developing treatments for rare diseases. Headquartered in Deer Park, Illinois, the company has successfully transitioned from a development-stage firm into a commercially focused entity with a diversified portfolio of orphan drugs.

2025 included the successful launch of KHINDIVI, the first FDA-approved oral solution formulation of hydrocortisone, in June. KHINDIVI was approved in May for pediatric patients five and older with adrenocortical insufficiency. The company is looking to expand the indication to younger patients with a revised formulation, and a bioequivalence study is expected to begin in early 2026.

The year also included high-performing relaunches of acquired assets Increlex, which treats a rare condition in which a child’s body does not produce enough growth factor-1, and the zinc therapy Galzin, a maintenance treatment for Wilson disease.

As of December, its portfolio included eight commercial products and five in its pipeline. The FDA is reviewing its new drug application for ET-600, with a decision scheduled for late February.

4. Fennec Pharmaceuticals (NASDAQ:FENC)

Year-to-date gain: 20.91 percent
Market cap: US$262.54 million
Share price: US$7.69

Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on preventing ototoxicity, meaning permanent hearing loss, in pediatric cancer patients undergoing cisplatin-based chemotherapy.

The company’s sole commercial product, Pedmark, is the first and only FDA-approved therapy specifically indicated to reduce the risk of hearing loss associated with cisplatin in patients one month of age and older with non-metastatic solid tumors.

Fennec experienced a pivotal year in 2025, marked by record revenue growth, entry into international markets and the elimination of corporate debt.

Additionally, data from a Phase 2/3 clinical study in Japan showed a significant reduction in the percentage of patients who experienced hearing loss, setting the stage for a 2026 global registration.

The company also began exploring its first major expansion into the adult cancer market through a new trial in metastatic testicular cancer.

5. Zevra Therapeutics (NASDAQ:ZVRA)

Year-to-date gain: 5.25 percent
Market cap: US$496.54 million
Share price: US$8.82

Zevra Therapeutics is a commercial-stage rare disease company that utilizes data-driven strategies to develop and commercialize transformational therapies for ultra-rare conditions.

Formerly known as KemPharm, the company rebranded in 2023 to reflect its evolution into a fully integrated pharmaceutical entity with a focus on high-unmet-need pediatric and metabolic disorders.

At the end of December, Zevra executed a strategic distribution agreement with Uniphar to provide its flagship product, Miplyffa, to patients outside of the US and Europe, broadening the drug’s global footprint. Miplyffa was approved by the FDA in 2024, and is indicated as a treatment for Niemann-Pick disease type C administered in combination with miglustat.

This announcement followed a strong Q3, in which the company reported a 605 percent year-over-year revenue increase, largely driven by the early success of Miplyffa.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

David Morgan, publisher of the Morgan Report, weighs in on silver’s record-setting price rise and what could be next for the white metal heading into 2026.

‘We’re still in price discovery. I truly believe that,’ he said.

‘What the true price of silver is in US dollars, Canadian dollars, I do not know. I think it’s north of $100 in US dollar terms, but it could be much higher than that.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Sydney, Australia (ABN Newswire) – Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) advised that recent reconnaissance and surface sampling programs have successfully identified a consistent northwest to southeast oriented mineralised corridor at the Mojave Project.

HIGHLIGHTS

– Results from rock chip sampling returns 409g/t Ag confirming high-grade silver mineralisation ~3km from the initial high-grade silver discovery (Sample 258140), 320m southwest of the Desert Antimony Mine (DAM)

– Significant base metal mineralisation confirmed in addition to silver, with samples returning grades up to 4.2% Copper (Cu), 1.5% Lead (Pb), and 1.5% Zinc (Zn), highlighting the polymetallic nature of the system

– Twelve (12) rock chip samples exceeded 30g/t Ag, reinforcing additional precious and base metal potential within the Mojave Project’s North Block

– This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project

This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project. The delineation of a mineralised corridor suggests a strike extent approximately 2.4km westnorthwest of the Hendricks Shaft, and approximately 600m to the east-southeast, extending the mineralised corridor almost 3km from the Silver Prospect. This confirms the presence of a polymetallic quartz vein system, which includes the high-grade sample 258140 collected from a 3cm to 10cm wide vein (Figure 1*). These early results possibly suggest that the Ag-Pb-Zn-Cu mineralisation may reflect the presence of a large-scale hydrothermal system, which could potentially contain valuable concentrations of precious and base metals. Further exploration is required to test this concept.

Rock chip sampling within the Mojave Project’s North Block has returned results of up to 409g/t Ag, with associated base metal values of up to 1.5% Zn and 0.88% Pb, supporting the interpretation of a polymetallic mineralised system and enhancing the prospectivity of the corridor. Additional rock chip sample 258420 returned values up to 117g/t Ag, & 3.1% Cu, also located within the interpreted mineralised corridor located close to a historic adit and workings.

The interpreted mineralised corridor includes the historic Hendricks Shaft, located approximately 2.4km from the initial high-grade silver discovery. A total of 398 rock chip samples have been collected across the North Block with ~260 of these being collected along the mineralised corridor between DAM and up to 5.6km to the southeast.

Rock Chip Sampling Program Details

The recent sampling campaign was designed to test the strike extent of the high-grade silver mineralisation first identified in late 2024. The results (see Table 1) have exceededexpectations, confirming that the mineralised system extends significantly beyond the initial discovery zone (Sample 258140 – Figure 1*).

Key observations from the program include:

– Strike Extension: The mineralised corridor is now interpreted to extend from the Silver Prospect (Sample 258140) to historical trenches and stockpiles (Samples 258184 & 258185) located ~3km to the south-east significantly increasing the strike extent of the exploration target.

– Mineralisation Style: High-grade samples 258184 and 258185, collected from outcropping veins and historic stockpiles, exhibit quartz with gossanous selvages with boxwork textures. These are potential indicators of weathered sulphide-rich polymetallic veins, suggesting fresh sulphides may exist at depth.

– Visual Copper: Sample 258420 (which returned 117g/t Ag & 3.1% Cu) was collected from outcropping mineralisation at historic workings where copper carbonate (i.e. malachite) is visually prevalent (see Figure 3*). This confirms a copper component to the mineralised system.

Next Steps

Locksley will advance this exciting silver and base metal opportunity through a systematic exploration program run in parallel with ongoing activities at DAM and El Campo, comprising:

– Systematic Mapping: Detailed geological mapping between the Silver Prospect and the new south-eastern extension to define the structural geometry and continuity of the trend.

– Petrology and Geochemistry: Submission of samples for petrological interpretation to assist with determining relative timing of mineralisation and geochemical associations across the system.

– Geophysics: Assessment of geophysical survey options, such as Very Low Frequency electromagnetics (VLF-EM), Induced Polarisation (IP), or Electromagnetic (e.g. VTEM) to potentially identify mineralised zones and structures at depth that are not visible at surface.

– Drill Targeting: The goal of this work is to delineate high-priority drill-ready targets along the NW-SE corridor for future testing.

Additional work is planned to improve understanding of the corridor’s structural geometry, enabling more effective drill targeting and delineation of the extent and grade of mineralisation within the North Block.

Kerrie Matthews, Managing Director & CEO, commented:

‘Defining a 3km mineralised trend with surface results of up to 409 g/t silver and 1.5% copper is a highly encouraging outcome. Importantly, this discovery complements our core antimony development strategy and gives exposure as a diversified U.S. critical minerals company, providing shareholders with upside to precious metals, base metals, and strategic minerals within a single, high-quality project area.’

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/R8C037M3

About Locksley Resources Limited:

Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) is an ASX listed explorer focused on critical minerals in the United States of America. The Company is actively advancing exploration across two key assets: the Mojave Project in California, targeting rare earth elements (REEs) and antimony. Locksley Resources aims to generate shareholder value through strategic exploration, discovery and development in this highly prospective mineral region.

Mojave Project

Located in the Mojave Desert, California, the Mojave Project comprises over 250 claims across two contiguous prospect areas, namely, the North Block/Northeast Block and the El Campo Prospect. The North Block directly abuts claims held by MP Materials, while El Campo lies along strike of the Mountain Pass Mine and is enveloped by MP Materials’ claims, highlighting the strong geological continuity and exploration potential of the project area.

In addition to rare earths, the Mojave Project hosts the historic ‘Desert Antimony Mine’, which last operated in 1937. Despite the United States currently having no domestic antimony production, demand for the metal remains high due to its essential role in defense systems, semiconductors, and metal alloys. With significant surface sample results, the Desert Mine prospect represents one of the highest-grade known antimony occurrences in the U.S.

Locksley’s North American position is further strengthened by rising geopolitical urgency to diversify supply chains away from China, the global leader in both REE & antimony production. With its maiden drilling program planned, the Mojave Project is uniquely positioned to align with U.S. strategic objectives around critical mineral independence and economic security.

Tottenham Project

Locksley’s Australian portfolio comprises the advanced Tottenham Copper-Gold Project in New South Wales, focused on VMS-style mineralisation

Source:
Locksley Resources Limited

Contact:
Kerrie Matthews
Chief Executive Officer
Locksley Resources Limited
T: +61 8 9481 0389
Kerrie@locksleyresources.com.au

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com

Perth, Australia (ABN Newswire) – Altech Batteries Ltd (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) announced that binding conditional funding approval in the amount of 46.11 million Euro has now been granted for the CERENERGY(R) Sodium-Chloride Solid-State battery project in Saxony, Germany. The grant approval materially derisks project funding and supports progression toward construction of the planned 120 MWh CERENERGY(R) battery manufacturing facility in Saxony, Germany.

Highlights

– Altech Batteries GmbH’s CERENERGY(R) battery project has received conditional binding funding approval under Germany’s federal ‘STARK’ economic development program.

– The approval relates to a grant covering approximately 30% of eligible project CAPEX, with funding of up to EUR46.11M.

– The funding commitment is conditional on achieving full project financial close by 30 June 2026 and parliamentary approval of funds under Germany’s 2026 Federal Budget.

Conditional Binding Funding Commitment

The funding is being provided as part of the federal STARK program, which is supported by the Federal Ministry for Economic Affairs and Energy in cooperation with the EU. The aim of this program is to lead regions undergoing structural change into an ecologically, economically and socially sustainable future.

With the approval of the funding, the project has successfully completed the second and decisive stage of the approval process. The funding covers approximately 30% of the eligible investment costs and represents a significant milestone for the construction of the planned 120 MWh CERENERGY(R) battery factory in Germany.

This decision underscores the importance of the innovative CERENERGY(R) technology, which is being developed in collaboration with the Fraunhofer Society. The Sodium-Chloride Solid-State battery offers a safe, sustainable and strategically independent alternative to lithium-ion batteries and is expected to play an important role in future stationary energy storage solutions – especially for the European market.

Mr Daniel Raihani, Managing Director & Chief Executive Officer, commented ‘Securing conditional binding funding approval of up to EUR46.11 million under Germany’s STARK program is a major milestone for the CERENERGY(R) project. The support reflects the strategic importance of establishing advanced, nonlithium energy storage manufacturing capability in Europe and recognises the technical progress achieved to date in collaboration with Fraunhofer IKTS.

‘Importantly, the grant materially de-risks the project’s capital structure by covering approximately 30% of eligible investment costs and provides a strong foundation as we progress toward full project financing and construction of the planned 120 MWh production facility in Saxony, Germany.

‘We remain focused on completing financial close by mid-2026 and advancing the CERENERGY(R) technology toward commercial deployment to support long-duration, safe and sustainable stationary energy storage solutions for the European market’.

As is customary for projects of this size, the funding commitment is subject to final financial close of the CERENERGY(R) battery project by June 2026 and budgetary approval of the funds in the 2026 federal budget.

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/918BT5H8

About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS (‘Fraunhofer’) to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech’s land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

Source:
Altech Batteries Ltd

Contact:
Daniel Raihani
Managing Director
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

Martin Stein
Chief Financial Officer
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com